ThermoGenesis Holdings Net Income 2006-2021 | THMO

ThermoGenesis Holdings net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ThermoGenesis Holdings Annual Net Income
(Millions of US $)
2020 $-16
2019 $-9
2018 $-40
2017 $
2017 $-29
2016 $-19
2015 $-15
2014 $-9
2013 $-3
2012 $-5
2011 $-3
2010 $-5
2009 $-9
2008 $-9
2007 $-7
2006 $-6
2005 $-8
ThermoGenesis Holdings Quarterly Net Income
(Millions of US $)
2021-06-30 $-5
2021-03-31 $-2
2020-12-31 $-3
2020-09-30 $-2
2020-06-30 $-6
2020-03-31 $-5
2019-12-31 $-4
2019-09-30 $-2
2019-06-30 $-1
2019-03-31 $-2
2018-12-31 $-7
2018-09-30 $-3
2018-06-30 $-27
2018-03-31 $-3
2017-12-31
2017-09-30 $-2
2017-06-30 $-1
2017-03-31 $-2
2016-12-31 $-3
2016-09-30 $-22
2016-06-30
2016-03-31 $-11
2015-12-31 $-1
2015-09-30 $-3
2015-06-30
2015-03-31 $-5
2014-12-31 $-4
2014-09-30 $-3
2014-06-30
2014-03-31 $-2
2013-12-31 $-2
2013-09-30 $-2
2013-06-30
2013-03-31 $-1
2012-12-31 $-1
2012-09-30 $1
2012-06-30
2012-03-31 $-2
2011-12-31 $-1
2011-09-30 $-1
2011-06-30
2011-03-31 $-1
2010-12-31 $-0
2010-09-30 $-0
2010-06-30
2010-03-31 $-1
2009-12-31 $-1
2009-09-30 $-2
2009-06-30
2009-03-31 $-1
2008-12-31 $-2
2008-09-30 $-3
2008-06-30
2008-03-31 $-3
2007-12-31 $-2
2007-09-30 $-2
2007-06-30
2007-03-31 $-1
2006-12-31 $-2
2006-09-30 $-1
2006-06-30
2006-03-31 $-1
2005-12-31 $-2
2005-09-30 $-2
2005-06-30
2005-03-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.021B $0.010B
ThermoGenesis Holdings Inc. develops, commercializes and markets automated technologies for CAR-T and other cell-based therapies. The company markets solutions for automated clinical biobanking, point-of-care applications and automation for immuno-oncology. ThermoGenesis Holdings Inc., formerly known as Cesca Therapeutics Inc., is based in Rancho Cordova, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00